Polymer-doxycycline conjugates as fibril disrupters: An approach towards the treatment of a rare amyloidotic disease
- 1 January 2015
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 198, 80-90
Abstract
No abstract availableKeywords
Funding Information
- Spanish Ministry (CTQ2010-18195/BQU, SAF2013-44844-R, AP2007-01665)
- GVA (ACOMP2013/186)
- Fundação para a Ciência e Tecnologia (FCT) (FCOMP-01-0124-FEDER-022718)
This publication has 45 references indexed in Scilit:
- Polymer therapeutics: Top 10 selling pharmaceuticals — What next?Journal of Controlled Release, 2014
- Peptide-Based Polymer TherapeuticsPolymers, 2014
- A versatile post-polymerization modification method for polyglutamic acid: synthesis of orthogonal reactive polyglutamates and their use in “click chemistry”Polymer Chemistry, 2013
- Polymer therapeutics-prospects for 21st century: The end of the beginningAdvanced Drug Delivery Reviews, 2013
- Demonstrating the importance of polymer-conjugate conformation in solution on its therapeutic output: Diethylstilbestrol (DES)-polyacetals as prostate cancer treatmentJournal of Controlled Release, 2012
- Polymer–drug conjugates as nano-sized medicinesCurrent Opinion in Biotechnology, 2011
- Nanomedicine(s) under the MicroscopeMolecular Pharmaceutics, 2011
- Conformational consequences of cooperative binding of a coiled-coil peptide motif to poly(N-(2-hydroxypropyl) methacrylamide) HPMA copolymersJournal of Controlled Release, 2011
- Polymer–Drug Conjugates for Novel Molecular TargetsNanomedicine, 2010
- Combination therapy: Opportunities and challenges for polymer–drug conjugates as anticancer nanomedicinesAdvanced Drug Delivery Reviews, 2009